Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma

Listen to expert faculty discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, with an emphasis on treatment selection across transplant-eligible and transplant-ineligible populations, the incorporation of proteasome inhibitors, and the tailoring of treatment intensity. The experts also examine unresolved questions regarding the optimal use of bortezomib, the role of autologous stem cell transplantation in the quadruplet era, and the use of MRD status to inform treatment decisions. Maintenance strategies with lenalidomide alone or in combination with anti-CD38 therapy are also discussed.